Warnex Inc.

Warnex Inc.

November 07, 2005 07:05 ET

Warnex sells Pathogen Detection System to University of Delaware

LAVAL, QC, Nov. 7 - Warnex Inc. (TSX:WNX) announced today that the
Lasher Laboratory of the University of Delaware, Georgetown, has purchased a
Warnex™ Rapid Pathogen Detection System to detect Salmonella in poultry.

The Lasher Laboratory provides diagnostic services to the producers of
commercial and non-commercial poultry in Delaware, and on the eastern shore of
Maryland and Virginia. With a state-of-the-art facility, the laboratory also
performs detection assays for new and emerging diseases such as avian
influenza, infectious bursal disease, infectious bronchitis, and Newcastle
disease. As part of the world-renowned University of Delaware poultry health
program, the Lasher Laboratory is committed to support the research, outreach
and educational programs of the University, which include interactions with
other universities, regulatory agencies, commercial companies and individuals.

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in
samples. The system allows for the simultaneous detection of multiple
pathogens and processing of samples within 12 to 48 hours, a significant
improvement over traditional microbiology tests that currently require 5 to 7
days.

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods and
GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our
development pipeline includes applications in the detection of viruses,
toxins, yeasts, and fungi, as well as meat speciation and bioterrorism.
Warnex's profitable and growing analytical, bioanalytical, and clinical
service groups offer a variety of quality control services, method development
and validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or
otherwise.

Contact Information